Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Nat Commun. 2021 May 5;12(1):2708. doi: 10.1038/s41467-021-23082-3.

Sho Iketani^{1

2}, Farhad Forouhar³, Hengrui Liu⁴, Seo Jung Hong⁵, Fang-Yu Lin⁶, Manoj S Nair¹, Arie Zask⁷, Yaoxing Huang¹, Li Xing⁶, Brent R Stockwell^{8

9}, Alejandro Chavez¹⁰, David D Ho^{11

12}

¹ Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA.
² Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
³ Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
⁴ Department of Chemistry, Columbia University, New York, NY, USA.
⁵ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
⁶ WuXi AppTec, Cambridge, MA, USA.
⁷ Department of Biological Sciences, Columbia University, New York, NY, USA.
⁸ Department of Chemistry, Columbia University, New York, NY, USA. bstockwell@columbia.edu.
⁹ Department of Biological Sciences, Columbia University, New York, NY, USA. bstockwell@columbia.edu.
¹⁰ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. ac4304@cumc.columbia.edu.
¹¹ Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA. dh2994@cumc.columbia.edu.
¹² Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA. dh2994@cumc.columbia.edu.

No abstract available

Publication types